Loading...
Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support
Objectives: Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) used as primary prophylaxis in patients receiving myelosuppressive chemotherapy regimens that have greater than 20% risk of developing febrile neutropenia (FN). Historically, pegfilgrastim has been administered 24 to 72 hou...
Na minha lista:
| Udgivet i: | Hosp Pharm |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7958366/ https://ncbi.nlm.nih.gov/pubmed/33790481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0018578719867659 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|